Gene Expression Test From XDx Now Indicated For Earlier Use And Prediction Of Acute Cellular Rejection

... XDx, a molecular diagnostics company, announced today expanded use and reimbursement for its first commercial offering, the AlloMap® molecular expression test.Data from a recent study show that AlloMap testing, a non-invasive method to detect the absence of acute cellular rejection in heart transplant recipients can now be used as early as two months post-transplant to rule out rejection. [click link for full article] ...